|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
ADR |
Shares
Out: |
58,240,000 |
Market
Cap: |
931.26(M) |
Last
Volume: |
115,349 |
Avg
Vol: |
115,030 |
52
Week Range: |
$9.64 - $17.22 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Avadel Pharmaceuticals is a biopharmaceutical company. Co.'s primary product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. Co.'s commercial products are: Akovaz, which is indicated for the treatment of hypotension occurring in the setting of anesthesia; Bloxiverz, which is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep®, which is for the treatment of hypotension occuring in the setting of anesthesia; and Nouress, which is a sterile injectable product for use in the hospital setting.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
2,000 |
41,000 |
370,500 |
Total Buy Value |
$0 |
$29,000 |
$558,597 |
$1,422,084 |
Total People Bought |
0 |
1 |
4 |
6 |
Total Buy Transactions |
0 |
1 |
5 |
18 |
Total Shares Sold |
0 |
75,000 |
103,975 |
103,975 |
Total Sell Value |
$0 |
$1,089,750 |
$1,522,364 |
$1,522,364 |
Total People Sold |
0 |
1 |
1 |
1 |
Total Sell Transactions |
0 |
1 |
2 |
2 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hatten Sandra L |
Sr. VP, Quality & Reg Affairs |
|
2016-03-18 |
4 |
B |
$11.01 |
$33,030 |
D/D |
3,000 |
3,000 |
2.74 |
- |
|
Anderson Michael S |
Chief Executive Office |
|
2016-03-14 |
4 |
B |
$9.74 |
$97,350 |
D/D |
10,000 |
124,250 |
2.81 |
- |
|
Stapleton Craig R |
Director |
|
2016-03-14 |
4 |
B |
$10.39 |
$1,039,400 |
D/D |
100,000 |
482,450 |
2.39 |
- |
|
Kotler Kevin |
10% Owner |
|
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,394,464 |
|
- |
|
Monteith David |
VP, Research and DevelopmentOf |
|
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,500 |
|
- |
|
Cerutti Guillaume |
Director |
|
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,000 |
|
- |
|
Stapleton Craig R |
Director |
|
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
382,450 |
|
- |
|
Anderson Michael S |
Chief Executive OfficerOfficer |
|
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
114,250 |
|
- |
|
Macke Scott A. |
VP, Supply Chain & OperationsO |
|
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
27,000 |
|
- |
|
Fildes Francis |
Director |
|
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,000 |
|
- |
|
Thompson Phillandas T. |
See RemarksOfficer |
|
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,000 |
|
- |
|
186 Records found
|
|
Page 8 of 8 |
|
|